Changes in peripheral blood mononuclear cell electrical properties in response to viral exposure and vaccination.

Publication date: Jul 09, 2025

Viral infection triggers both cellular and systemic responses in vivo. These are sometimes difficult to study since the immune system is subject to constant challenge from multiple pathogens. However, during the COVID-19 pandemic, a unique opportunity arose to measure the body’s immune response during lockdown, when exposure to pathogens from the environment was substantially lower. This allowed measurement of COVID-nacEFve patients, as well as those who had recovered from COVID-19. The effects of subsequent vaccination and boosters could also be assessed. This offers two advantages; an insight into the humoral response to novel pathogens, and the opportunity to measure the ability of the body to respond to challenge from both new pathogens and those to which exposure had already occurred. In this paper, we used dielectrophoresis (DEP) to analyze the electrophysiological fingerprint of peripheral blood mononuclear cells (PBMCs) from donors who had never had COVID-19, those who had recovered from COVID-19, and those who received first, second, or third vaccine doses. This was performed before and after incubation with the receptor binding domain of the SARS-CoV-2 spike protein to determine whether differential changes in the electrical properties of PBMCs could be detected and evaluated. Clear trends in response over time were observed, suggesting that DEP could pave the way towards a new correlate of protection (CoP) to SARS-CoV-2. Furthermore, since the test measures immune response to challenge, it may be widely applicable to other diseases.

Open Access PDF

Concepts Keywords
Cop Adult
Dielectrophoresis Correlate of protection
Donors COVID-19
Humoral COVID-19 Vaccines
Vaccine COVID-19 Vaccines
Cytoplasmic conductivity
Dielectrophoresis
Female
Humans
Leukocytes, Mononuclear
Male
Membrane capacitance
Membrane conductance
Middle Aged
SARS-CoV-2
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Vaccination

Semantics

Type Source Name
disease IDO blood
disease IDO cell
disease MESH Viral infection
pathway REACTOME Immune System
disease MESH COVID-19 pandemic
disease IDO immune response
drug DRUGBANK Creatinolfosfate
disease MESH Long Covid
disease IDO organism
disease IDO process
disease IDO primary infection
disease MESH reinfection
disease MESH respiratory tract infections
disease MESH pneumonia
disease MESH syndrome
drug DRUGBANK Coenzyme M
disease MESH death
disease MESH infection
disease IDO protein
disease IDO symptom
drug DRUGBANK Heparin
drug DRUGBANK Streptomycin
drug DRUGBANK Dihydrocodeine
disease IDO host
drug DRUGBANK Water
drug DRUGBANK Sucrose
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Aspartame
drug DRUGBANK Chromium
disease IDO reagent
drug DRUGBANK L-Aspartic Acid
disease IDO immune population

Original Article

(Visited 4 times, 1 visits today)